Keyphrases
Neuroblastoma
82%
TIGIT
38%
Nectin-2
38%
Single-cell RNA Sequencing (scRNA-seq)
38%
Integrative Analysis
38%
High-risk Neuroblastoma
28%
Complete Remission
24%
3-methoxytyramine
22%
Patient Characteristics
19%
Aberrations
19%
Tumor Characteristics
19%
Multiorgan Donor
19%
Mutational Spectrum
19%
Breast Cancer
19%
Transplant Recipients
19%
Immunomodulatory
19%
Complete Response
19%
Urinary Catecholamines
19%
Catecholamines
16%
Tumor
14%
Spot Urine
13%
B Cells
9%
Immune Checkpoint
9%
Combination Strategy
9%
Pediatric Patients
9%
Treatment Options
9%
Effective Treatment
9%
Interaction Analysis
9%
Programmed Death-ligand 1 (PD-L1)
9%
Syngeneic Model
9%
NKT Cells
9%
Immunotherapy Efficacy
9%
Immunotherapeutics
9%
Promising Target
9%
Poor Survival
9%
Post-chemotherapy
9%
Chemotherapy Resistance
9%
Survival Rate
9%
T Cells
9%
Reduced Cytotoxicity
9%
Relapse Prevention
9%
Natural Killer Cells
9%
PD-1 Blockade
9%
Exon Deletion
8%
Overall Survival
8%
Poor Prognosis
7%
Missense
5%
ATRX mutation
5%
In Vitro Diagnostics
5%
Event-free Survival
5%
Medicine and Dentistry
Ganglioneuroblastoma
100%
Neoplasm
45%
RNA Sequence
38%
Immunotherapy
38%
Urinary System
38%
Solid Malignant Neoplasm
21%
Patient with Neuroblastoma
21%
Biological Marker
21%
3-Methoxytyramine
21%
Transplantation
19%
Breast Cancer
19%
Diseases
19%
Neuroblastoma Cell Line
19%
Pediatrics
19%
Drug Sensitivity
19%
Personalized Medicine
19%
Liquid Biopsy
19%
Catecholamine
19%
Transcriptomics
19%
Organoid
19%
Programmed Death-Ligand 1
15%
T Cell
15%
High Throughput Screening
14%
Clinical Decision Making
12%
Chemotherapy
11%
Pediatrics Patient
10%
Tumor
9%
Organ Donor
7%
Survival Rate
7%
Immunosuppressive Drug
7%
Natural Killer Cell
7%
Cytotoxicity
7%
B Cell
7%
Natural Killer Cell
7%
Cell Line
7%
Prognostication
7%
Rhabdomyosarcoma
7%
Overall Survival
6%
Primary Tumor
5%
